Preclinical impact of bevacizumab on brain and tumor distribution of irinotecan and temozolomide

Journal of Neuro-oncology
Lauriane GoldwirtChristine Fernandez

Abstract

Glioblastoma (GBM) is the most common primary malignant brain tumour in adults. Prognosis of GBM patients is poor with median overall survival around 15 months. Temozolomide is the chemotherapeutic agent used in the standard of care of newly diagnosed GBM patients relying on radiotherapy with concurrent chemotherapy followed by chemotherapy alone. Irinotecan has shown some efficacy in recurrent malignant gliomas. Bevacizumab has been combined with irinotecan in the treatment of recurrent GBM and with temozolomide in newly diagnosed GBM. As the efficacy of GBM treatments relies on their brain distribution through the blood brain barrier, the aim of the present preclinical work was to study, in in vivo models, the impact of bevacizumab on brain and tumor distribution of temozolomide and irinotecan. Our results show that bevacizumab pre-treatment was associated with a reduced temozolomide brain distribution in tumor-free mice. In tumor bearing mice, bevacizumab increased temozolomide tumor distribution, although not statistically significant. In both tumor-free and tumor-bearing mice, bevacizumab does not modify brain distribution of irinotecan and its metabolite SN-38. Bevacizumab impacts brain distribution of some anti-tumor dru...Continue Reading

Associated Clinical Trials

References

Mar 1, 1991·Journal of Neurosurgery·T MatsumotoK Miyaji
Jan 1, 1989·Proceedings of the National Academy of Sciences of the United States of America·C Cordon-CardoJ R Bertino
Jun 1, 1988·Journal of Pharmacokinetics and Biopharmaceutics·A J Bailer
Nov 9, 1995·Biochemical Pharmacology·L JettéR Beliveau
May 23, 1998·Annual Review of Pharmacology and Toxicology·T Satoh, M Hosokawa
May 20, 1999·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·H S FriedmanL L Miller
Jun 6, 2000·Advanced Drug Delivery Reviews·T Terasaki, K Hosoya
Jun 8, 2001·International Journal of Cancer. Journal International Du Cancer·M DemeuleR Béliveau
Mar 27, 2002·Cancer Chemotherapy and Pharmacology·Lalitha IyerUlrich Mayer
Jun 24, 2004·Brain Research. Brain Research Reviews·Marnix JansenCornelis J F van Noorden
Mar 11, 2005·The New England Journal of Medicine·Roger StuppUNKNOWN National Cancer Institute of Canada Clinical Trials Group
Nov 8, 2005·Toxicology in Vitro : an International Journal Published in Association with BIBRA·Nicola F SmithAlex Sparreboom
Mar 15, 2006·Neuro-oncology·Michael D PradosUNKNOWN North American Brain Tumor Consortium
Oct 10, 2006·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·E M KemperO van Tellingen
Jul 10, 2007·Biochemical and Biophysical Research Communications·Naoki OkaToru Iwama
Jan 12, 2008·Molecular Cancer Therapeutics·An ClaesWilliam P J Leenders
Aug 9, 2008·Annals of Oncology : Official Journal of the European Society for Medical Oncology·M SchaichD Krex
Dec 3, 2008·Neoplasia : an International Journal for Oncology Research·Véronique MathieuFlorence Lefranc
May 24, 2011·Clinical Medicine Insights. Oncology·Marc C Chamberlain
Jul 27, 2011·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Louisa von BaumgartenFrank Winkler
Jul 27, 2012·Journal of Neuro-oncology·Chiara CalatozzoloMarta Maschio
Mar 7, 2013·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Fan LinOlaf van Tellingen
Feb 21, 2014·The New England Journal of Medicine·Mark R GilbertMinesh P Mehta
Feb 21, 2014·The New England Journal of Medicine·Olivier L ChinotTimothy Cloughesy
May 29, 2014·Cancer Chemotherapy and Pharmacology·Lauriane GoldwirtChristine Fernandez

❮ Previous
Next ❯

Citations

Aug 31, 2019·Journal of Oncology·Carlos VelásquezJosé L Fernández-Luna
Jul 1, 2016·Chinese Journal of Cancer·Ilaria Fuso NeriniRaffaella Giavazzi
Oct 16, 2015·Expert Review of Neurotherapeutics·Omar Abdel-Rahman, Mona Fouad

❮ Previous
Next ❯

Related Concepts

Related Feeds

Blood Brain Barrier Chips

The blood brain barrier (BBB) is comprised of endothelial cells that regulate the influx and outflux of plasma concentrations. Lab-on-a-chip devices allow scientists to model diseases and mechanisms such as the passage of therapeutic antibodies across the BBB. Discover the latest research on BBB chips here.

Blood Brain Barrier

The blood brain barrier is a border that separates blood from cerebrospinal fluid. Discover the latest search on this highly selective semipermeable membrane here.

Related Papers

Cancer Chemotherapy and Pharmacology
Lauriane GoldwirtChristine Fernandez
JAMA Neurology
Alissa A ThomasAntonio M Omuro
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
James J VredenburghHenry S Friedman
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
Helen AthanassiouPantelis Karageorgis
© 2021 Meta ULC. All rights reserved